These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22093474)

  • 21. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine.
    Madhi SA; Cutland C; Jones S; Groome M; Ortiz E
    S Afr Med J; 2011 Nov; 101(12):879-83. PubMed ID: 22273029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants.
    Kosalaraksa P; Thisyakorn U; Benjaponpitak S; Chokephaibulkit K; Santos-Lima E
    Int J Infect Dis; 2011 Apr; 15(4):e249-56. PubMed ID: 21334243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
    Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
    Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants.
    Li Y; Li RC; Ye Q; Li C; Liu YP; Ma X; Li Y; Zhao H; Chen X; Assudani D; Karkada N; Han HH; Van Der Meeren O; Mesaros N
    Hum Vaccin Immunother; 2017 Mar; 13(3):588-598. PubMed ID: 27768515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand.
    Thisyakorn U; Chotpitayasunondh T; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):450-62. PubMed ID: 20578530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
    Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM
    Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age.
    Lin TY; Wang YH; Chang LY; Chiu CH; Huang YC; Tang H; Bock HL
    Chang Gung Med J; 2003 May; 26(5):315-22. PubMed ID: 12934847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.
    Omeñaca F; Garcia-Sicilia J; Boceta R; Sistiaga-Hernando A; García-Corbeira P
    Pediatr Infect Dis J; 2007 Sep; 26(9):824-9. PubMed ID: 17721379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
    Chotpitayasunondh T; Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2012 Mar; 43(2):442-54. PubMed ID: 23082595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P; Arguedas Mohs A; Abdelnour Vásquez A; Consuelo-Miranda M; Feroldi E; Noriega F; Jordanov E; B Chir S; Zambrano B
    Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective, observational, multi-center, post-marketing safety surveillance study of the GSK combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and
    Elenge DM; Heo JS; Kim SS; Kim YK; Lee JH; Xavier S; Bahar E; Dos Santos G; Guignard A
    Hum Vaccin Immunother; 2024 Dec; 20(1):2406060. PubMed ID: 39376187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.
    Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A
    Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine.
    Greenberg DP; Wong VK; Partridge S; Chang SJ; Jing J; Howe BJ; Ward JI
    Pediatr Infect Dis J; 2000 Dec; 19(12):1135-40. PubMed ID: 11144372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America.
    Macías M; Lanata CF; Zambrano B; Gil AI; Amemiya I; Mispireta M; Ecker L; Santos-Lima E
    Pediatr Infect Dis J; 2012 Aug; 31(8):e126-32. PubMed ID: 22531237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.